Dashboard
Manage Tickers

OPRXOptimizeRx Corp

Nasdaq optimizerx.com


$ 7.73 $ -0.07 (-0.9 %)    

Monday, 16-Sep-2024 15:59:41 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 473.16 $ -2.18 (-0.46 %)
DIA $ 417.33 $ 2.39 (0.58 %)
SPY $ 562.46 $ 0.45 (0.08 %)
TLT $ 101.29 $ 0.88 (0.88 %)
GLD $ 238.61 $ -0.07 (-0.03 %)
$ 7.8
$ 7.84
$ 7.72 x 200
-- x --
$ 7.63 - $ 7.92
$ 6.92 - $ 16.65
63,958
na
142.41M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-15-2024 06-30-2024 10-Q
2 05-15-2024 03-31-2024 10-Q
3 04-15-2024 12-31-2023 10-K
4 11-14-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-12-2023 03-31-2023 10-Q
7 03-10-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-04-2021 06-30-2021 10-Q
14 05-06-2021 03-31-2021 10-Q
15 03-08-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-05-2020 06-30-2020 10-Q
18 05-06-2020 03-31-2020 10-Q
19 03-26-2020 12-31-2019 10-K
20 11-05-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-05-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-02-2018 03-31-2018 10-Q
27 03-08-2018 12-31-2017 10-K
28 11-02-2017 09-30-2017 10-Q
29 08-01-2017 06-30-2017 10-Q
30 05-03-2017 03-31-2017 10-Q
31 03-08-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-15-2016 12-31-2015 10-K
36 11-12-2015 09-30-2015 10-Q
37 08-11-2015 06-30-2015 10-Q
38 05-14-2015 03-31-2015 10-Q
39 03-31-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

optimizerx-reports-expansion-of-strategic-relationship-with-a-major-pharma-client
OptimizeRx Reports Expansion Of Strategic ...
09/10/2024 11:48:16

The company announced an expansion of a strategic relationship with a major pharma client via a muti-solution, multi-brand prog...

optimizerx-launches-micro-neighborhood-targeting-offered-on-the-cos-dynamic-audience-activation-platform-further-unifing-outreach-to-patient-and-provider-audiences-via-the-incorporation-of-brand-eligibility-signals-to-consumer-marketing
OptimizeRx Launches Micro-Neighborhood Tar...
09/09/2024 16:04:50

The availability of Micro-Neighborhood® Targeting on the Company's Dynamic Audience Activation Platform meets the demand of...

rbc-capital-maintains-outperform-on-optimizerx-lowers-price-target-to-14
RBC Capital Maintains Outperform on Optimi...
08/16/2024 15:25:29

RBC Capital analyst Sean Dodge maintains OptimizeRx (NASDAQ:OPRX) with a Outperform and lowers the price target from $17 to ...

a-closer-look-at-5-analyst-recommendations-for-optimizerx
A Closer Look at 5 Analyst Recommendations...
08/12/2024 14:00:13

barclays-maintains-equal-weight-on-optimizerx-lowers-price-target-to-11
Barclays Maintains Equal-Weight on Optimiz...
08/12/2024 12:24:16

Barclays analyst Stephanie Davis maintains OptimizeRx (NASDAQ:OPRX) with a Equal-Weight and lowers the price target from $15...

optimizerx-reiterates-2024-guidance-and-expects-revenue-to-be-at-least-100m-est-101458m-with-adjusted-ebitda-of-at-least-11m
OptimizeRx Reiterates 2024 Guidance And Ex...
08/08/2024 21:31:20

optimizerx-q2-2024-adj-eps-002-beats-006-estimate-sales-18812m-miss-20195m-estimate
OptimizeRx Q2 2024 Adj. EPS $0.02 Beats $(...
08/08/2024 20:59:44

OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.06) by...

jmp-securities-reiterates-market-outperform-on-optimizerx-maintains-16-price-target
JMP Securities Reiterates Market Outperfor...
06/24/2024 15:42:12

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 pr...

critical-insights-from-optimizerx-analyst-ratings-what-you-need-to-know
Critical Insights From OptimizeRx Analyst ...
06/21/2024 16:01:18

jmp-securities-reiterates-market-outperform-on-optimizerx-maintains-16-price-target
JMP Securities Reiterates Market Outperfor...
06/21/2024 15:03:19

JMP Securities analyst Constantine Davides reiterates OptimizeRx (NASDAQ:OPRX) with a Market Outperform and maintains $16 pr...

gold-rises-over-1-arcos-dorados-shares-fall-after-q1-results
Gold Rises Over 1%; Arcos Dorados Shares F...
05/15/2024 18:33:38

jmp-securities-maintains-market-outperform-on-optimizerx-raises-price-target-to-16
JMP Securities Maintains Market Outperform...
05/15/2024 17:42:04

JMP Securities analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price ...

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

12-health-care-stocks-moving-in-wednesdays-intraday-session
12 Health Care Stocks Moving In Wednesday'...
05/15/2024 16:31:58

nasdaq-surges-150-points-retail-sales-flat-for-april
Nasdaq Surges 150 Points; Retail Sales Fla...
05/15/2024 16:05:39

expert-ratings-for-optimizerx
Expert Ratings For OptimizeRx
05/15/2024 13:00:52

stifel-maintains-buy-on-optimizerx-maintains-13-price-target
Stifel Maintains Buy on OptimizeRx, Mainta...
05/15/2024 11:51:54

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and maintains $13 price target.

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

optimizerx-reiterates-fy24-guidance-with-revenue-to-be-at-least-100m-est-101313m-adjusted-ebitda-of-at-least-11m
OptimizeRx Reiterates FY24 Guidance With R...
05/14/2024 20:29:42

optimizerx-q1-adj-011-beats-013-estimate-sales-1969m-beat-1813m-estimate
OptimizeRx Q1 Adj $(0.11) Beats $(0.13) Es...
05/14/2024 20:12:34

OptimizeRx (NASDAQ:OPRX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.13) by...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION